For members of the public:
Reslizumab
Overview
This will allow quick identification of new safety information. The Patient Information Leaflet for products containing Reslizumab from Teva can be downloaded below, along with other information such as Frequently Asked Questions where applicable. To contact Teva's Medical Information Service email: medinfo@tevauk.com or telephone: 0207 540 7117.
Available as
- Concentrate for Infusion
Date of preparation: April 2023
D: COB-GB-NP-00112 (V1.0) / T: COB-GB-NP-00102 (V1.0) / M: COB-GB-NP-00103 (V1.0)
Date of preparation: April 2023
D: COB-GB-00016 (V1.0) / T: COB-GB-00014 (V1.0) / M: COB-GB-00015 (V1.0)
Date of preparation: April 2023
D: COB-GB-NP-00104 (V1.0) / T: COB-GB-NP-00105 (V1.0) / M: COB-GB-NP-00106 (V1.0)